History
Documents created during the development process.
Background information
-
-
Appendix A: Decision paper presented to the Institute's Guidance Executive
-
Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)
-
NICE guidance recommends treatment for severe plaque psoriasis (PDF 70 KB)
Psoriasis - ustekinumab: final appraisal determination
-
Psoriasis - ustekinumab: final appraisal determination information
-
Psoriasis - ustekinumab: final appraisal determination
-
Psoriasis - ustekinumab: final appraisal determination (PDF 134 KB)
-
Response to consultee, commentator and public comments on the appraisal consultation document (ACD)
-
-
Consultee and commentator comments on the ACD
-
Janssen-Cilag
-
-
British Association of Dermatologists
-
-
Psoriasis and Psoriatic Arthritis Alliance
-
-
Royal College of Physicians
-
-
Royal College of Nursing
-
-
Department of Health
-
-
Dorset PCT
-
-
Welsh Assembly Government
-
-
Abbott Laboratories
-
-
Schering-Plough
-
-
Wyeth Pharmaceutical
-
Psoriasis - ustekinumab: appraisal consultation
-
-
Psoriasis - ustekinumab: appraisal consultation document information
-
Psoriasis - ustekinumab: evaluation report
-
Psoriasis - ustekinumab: pre-meeting briefing
-
-
Psoriasis - ustekinumab: Evidence Review Group report
-
Psoriasis - ustekinumab: Evidence Review Group report (PDF 1.48 MB)
-
Psoriasis - ustekinumab: Non-manufacturer submissions
-
Psoriasis - ustekinumab: Non-manufacturer submissions - British Association of Dermatologists
-
-
Psoriasis - ustekinumab: Non-manufacturer submissions - Dorset PCT
-
Psoriasis - ustekinumab: Non-manufacturer submissions - Dorset PCT (PDF 62 KB)
-
Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis Association
-
Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis Association (PDF 49 KB)
-
Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis and Psoriatic Arthritis Alliance
-
-
Psoriasis - ustekinumab: Non-manufacturer submissions - The Royal College of Physicians
-
Psoriasis - ustekinumab: Non-manufacturer submissions - The Royal College of Physicians (PDF 50 KB)
-
Psoriasis - ustekinumab: Manufacturer submission
-
Psoriasis - ustekinumab: Manufacturer submission - Janssen-Cilag
-
Psoriasis - ustekinumab: Manufacturer submission - Janssen-Cilag (PDF 2.52 MB)
-
Psoriasis - ustekinumab: Manufacturer submission - NICE clarification letter
-
Psoriasis - ustekinumab: Manufacturer submission - NICE clarification letter (PDF 27 KB)
-
Psoriasis - ustekinumab: Manufacturer submission - Manufacturer response to clarification letter
-
-
Psoriasis - ustekinumab: Expert written personal statements
-
Psoriasis - ustekinumab: Expert written personal statements - Anstey information
-
Psoriasis - ustekinumab: Expert written personal statements - Anstey (PDF 20 KB)
-
Psoriasis - ustekinumab: Expert written personal statements - Barker information
-
Psoriasis - ustekinumab: Expert written personal statements - Barker (PDF 21 KB)
-
Psoriasis - ustekinumab: Expert written personal statements - Jobling information
-
Psoriasis - ustekinumab: Expert written personal statements - Jobling (PDF 20 KB)
-
Psoriasis - ustekinumab: Expert written personal statements - McAteer information
-
Psoriasis - ustekinumab: Expert written personal statements - McAteer (PDF 20 KB)
Psoriasis - ustekinumab: final scope
-
Psoriasis - ustekinumab: final scope
-
Psoriasis - ustekinumab: stakeholder comments on the draft remit
-
Psoriasis - ustekinumab: stakeholder comments on the draft remit
-
Psoriasis - ustekinumab: stakeholder comments on the draft remit (PDF 106 KB)
Psoriasis - ustekinumab: stakeholder comments on the provisional matrix of consultees and commentators
-
Psoriasis - ustekinumab: stakeholder comments on the provisional matrix of consultees and commentators
-